Crossmark

BRCA1/2 testing: therapeutic implications for breast cancer management

Crossref DOI link: https://doi.org/10.1038/s41416-018-0127-5

Published Online: 2018-06-05

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tung, Nadine M.

Garber, Judy E.
License Information

Text and Data Mining valid from 2018-06-05
More Information

Article History

Received: 29 September 2017

Revised: 10 April 2018

Accepted: 24 April 2018

First Online: 5 June 2018

Competing interests

: N.M.T. reports research funding from Ambry Genetics (no salary support). J.E.G. reports consulting for Biogen, Helix, Novartis (spouse), GTx (spouse), and research support from Ambry Genetics, Novartis (spouse).